BRIEF—PhoreMost hits milestone in Boehringer pact

A milestone payment has been triggered in an ongoing collaboration between Cambridge, UK-based drug discovery firm PhoreMost and Germany’s Boehringer Ingelheim.

The British firm has now identified and validated novel targets for further development, supporting Boehringer’s goal to develop first-in-class therapies.

The multi-project collaboration, initiated in January 2020, is based around PhoreMost’s next-generation phenotypic screening platform, SITESEEKER.

Chief executive Neil Torbett said the project “provides significant validation of our SITESEEKER platform and its capabilities in novel target discovery.”